PERSONAL
INFORMATION
HuangXiuyan, associate chief physician, associate professor, Department of general surgery, Shanghai Jiao Tong University Affiliated
Sixth People’s Hospital.
EDUCATION
2014–2015
Dana-Farber Cancer Institute (DFCI), Brigham and Women’s Hospital (BWH) of
Harvard Medical, School (HMS) affiliated to Harvard University, Division of
Surgical Oncology, Postdoctoral Fellow
2003–2008
Zhong shan Hospital, Medical College of Fudan University, liver surgery, MD
HONORS AND AWARDS
2016 Outstanding
employee, Shanghai 6th People’s Hospital, Shanghai Jiao Tong University
2013 Outstanding
employee, Shanghai 6th People’s Hospital, Shanghai Jiao Tong University
2010 Excellent
surgical chief resident, Shanghai 6th People’s Hospital, Shanghai Jiao Tong
University
2008 Advanced
individual of college students’ social practice in Shanghai
RESEARCH EXPERIENCE
Jan 2016
– current “The International Foundation of Translational Medicine for Abroad
Scholars and Students, U.S. and China” (No. UCTMP2015-03C001).
Jan 2013
– 2016 “Intervention and molecular mechanism underlying the interaction effect
between MIM-B and Caveolin-1 on EGFR endocytic cycle in hepatocellular
carcinoma” (NSFC 81272401) granted by the National Natural Science Foundation
of China.
Jan 2011
– Dec 2012 “Basic research of in vivo inhibitive efficacy of substances of
Chinese herbal compound Songyou Yin on human hepatocellular carcinoma”
(2010L059A) granted by Shanghai Municipal Health Bureau, China.
Jan 2010
– Dec 2011 “Effect of MIM-B on invasive potential of hepatocellular carcinoma
in vitro and in vivo” (Hospital-1131) granted by Shanghai 6th People’s
Hospital, China.
2005 –
2008 “The effect of palliative liver resection on invasive and metastatic
potential of residual hepatocellular carcinoma”, the State Key Basic Research
Program of China grants 2004CB518700, China.
Part of Involved Research Program:
Jan 2013
– Dec 2014 “Optimization of Chinese herbal compound Songyou Yin and MRI
assessment” (2012QJ001A) funded by Shanghai Municipal Health Bureau, China.
Jan 2006
– Dec 2008 “Resistance and molecular mechanisms of autophagy of cell lines of
hepatocellular carcinoma with high metastatic potential” (30571801) funded by
the National Natural Science Foundation of China.
Jan 2006
– Dec 2008 “The relationship between the hepatic sinus blood capillary and the
rejection after liver transplantation” (30500472) funded by the National
Natural Science Foundation of China.
Jan 2006
– Dec 2008 “Protein molecular markers for micro portal venous tumor emboli of
hepatocellular carcinoma” (30600605) funded by the National Natural Science
Foundation of China.
Jun 2010 –
May 2012 “Molecular biological compatibility study of Biodegradable magnesium
alloy with bile duct epithelial cell” (YG2010MS45) funded by Shanghai Jiao Tong
University, China.
WORK EXPERIENCE
2013 –
current Associate chief physician The Shanghai 6th People’s Hospital,
Shanghai Jiao Tong University
2011 –
2012 Attending The Shanghai 6th People’s
Hospital, Shanghai Jiao Tong University
2010 –
2011 Chief resident The Shanghai 6th
People’s Hospital, Shanghai Jiao Tong University
2008 –
2009 Surgical resident and chief
resident training The Shanghai 6th
People’s Hospital, Shanghai Jiao Tong University
2003 –
2008 Surgical resident and chief
resident training The Zhongshan
Hospital, Fudan Universsity
1999 –
2002 Surgical resident The 6th
People’s Hospital, Wuhu City, China
PUBLICATIONS IN RECENT YEARS(2009-2014)
Co-first
Author
1 The chemokine CXCL9 expression is
associated with better prognosis for colorectal carcinoma patients [J]. Biomed
Pharmacother, 2016, 8: 8–13.
2 Distribution of lymphocyte subpopulations
in thyroid glands of human autoimmune thyroid disease. J Clin Lab Anal, 2014,
28 (3): 249–254.
3 Cancer targeting gene-viro-therapy for
pancreatic cancer using oncolytic adenovirus ZD55-IL-24 in immune-competent
mice. Mol Bio Rep, 2013, 40 (9): 5397–5405.
First
Author
1 Comprehensive circular RNA profiling
reveals the regulatory role of the circRNA-100338/miR-141-3p pathway in
hepatitis B-related hepatocellular carcinoma. Sci Rep, 2017, 7 (1): 5428.
2 Gambogic acid sensitizes gemcitabine
efficacy in pancreatic cancer by reducing the expression of ribonucleotide
reductase subunit-M2 (RRM2). J Exp Clin Cancer Res, 2017, 36(1): 107.
3 Missing-in-metastasis MIM-B combined with
caveolin-1 promotes the metastatic potential of hepatocellular carcinoma.
Oncotarget, 2017.7.18, under production.
4 Interaction between missing in metastasis
B and caveolin-1 in hepatocellular carcinoma. Chin J Exp Surg, 2017, 34 (6):
963–969.
5 Pancreatic cancer cell-derived IGFBP-3
contributes to muscle wasting [J]. J Exp Clin Cancer Res, 2016, 35: 46.
6 Elevated MTSS1 expression associated with
metastasis and poor prognosis of residual hepatitis B-related hepatocellular
carcinoma [J]. J Exp Clin Cancer Res. 2016, 35(1):85.
7 A case of multiple primary malignancies
and investigation of family history. Oncol Lett, 2012, 4(5), 931–934.
8 Herbal compound Songyou Yin reinforced
interferon–Alfa to inhibit the enhanced metastatic potential induced by
palliative resection of hepatocellular carcinoma in nude mice. BMC Cancer,
2010, 10, 580.
9 Effects of the dysregulation in
Hedgehog–Gli singnaling pathway on the growth and metastatic potential of human
hepatocellular carcinoma, and its advances of molecular targeted therapy. U.S
Chinese J of Lymphology and Oncology, 2010, 9 (2): 49–53.
10 Role of MIM/MIM–B in human tumor
progression. U.S Chinese J of Lymphology and Oncology, 2010, 9 (3): 104–108.
11 Herbal compound extract Songyou Yin inhibits
tumor growth and prolongs survival in nude mice bearing human hepatocellular
carcinoma xenograft with high metastatic potential. J Cancer Res Clin Oncol,
2009, 135 (9): 1245–1255.
12 The experimental research on the apoptosis
of hepatocellular carcinoma induced by Chinese herbal compound Songyou Yin.
Chinese Archives of Traditional Chinese Medicine, 2014, 32 (2): 249–251.
13 A case with rectal cancer relapse after
clinical complete remission after neoadjuvant chemoradiotherapy. Chin J
Clinicians (Electronic Edition), 2013, 7(17): 8079–8081.
14 Preliminary research on effective substances
of Chinese herbal compound Songyou Yin in vivo. Chinese Archives of Traditional
Chinese Medicine, 2013, 31 (5): 979–983.
15 Establishment of metastatic molecule
diagnostic model for hepatocellular carcinoma. Chin J Exp Surg, 2013, 30 (5):
1072–1074.
16 Establishment of a high metastatic potential
human hepatocellular carcinoma orthotopic transplantation model with palliative
liver resection in nude mice. Chin J Hepatol, 2013, 21 (8): 604–608.
17 Experimental research on the enhanced
invasive potentials of human hepatocelluar carcinoma following palliative
resection. Chin J Clinicians (Electronic Edition), 2011, 5 (2): 479–481.
18 In vitro inhibitory effect of sorafenib on
proliferation of human hepatocellular carcinoma cells with differential pERK
expression reinforced by lentivirus-mediated small RNA interference targeting
MIM-B gene. Chin J Exp Surg, 2011, 28 (2): 396–398.
19 Experimental research on inhibition of
interferon-alfa on hepatocellular carcinoma reinforced by Chinese herbal
compound Songyou Yin. CJTCMP, 2011, 26 (12): 2859–2861.
20 Analysis of the Effects of Chinese Herbal
Compound Songyou Yin in vitro and in vivo. Chinese Archives of Traditional
Chinese Medicine, 2011, 29 (11): 2542–2544.
21 Experimental observation of the effects of
Chinese herbal compound Songyou Yin combined with interferon–alpha on the
growth and metastasis of residual hepatocellular carcinoma in nude mice model
of palliative resection. J Clini Hepatol, 2011, 27 (5): 482–484.
22 A case with multiple primary malignancies.
Chin J Med Genet, 2011, 28 (4): 471–472.
23 Inhibition effects of Chinese herbal
compound prescription of Songyouyin on orthotopic tumor in nude mice bearing
human hepatocellular carcinoma xenografts with high metastatic potential.
CJTCMP, 2010, 25 (2): 234–237.
24 Role of proteins of missing in metastasis in
cancer initiation and progression. Tumor, 2010, 30 (2): 170–172.
25 Effects of Hedgehog–Gli singnaling pathway in
hepatocellular carcinoma. Chin J Cancer Prev Treat, 2010, 17 (6): 471–474.
26 Experimental observation on the alteration
of metastatic potential and its gene function net of residual hepatocellular
carcinoma following palliative liver resection. Natl Med J China, 2010, 90
(18): 1278–1282.
27 The criteria of hepatectomy for
hepatocellular carcinoma and its clinical significance. Chinese Journal of
Clinical Oncology, 2010, 37 (9): 533–535.
28 Study on fingerprints of Chinese herbal
compound Songyou Yin and its component extracts by high performance liquid
chromatograpy. Chinese Archives of Traditional Chinese Medicine, 2010, 28 (7):
1389–1392.
29 Experimental research on inhibition effects
of Chinese herbal compound Songyou Yin on tumor growth and metastasis of
residual hepatocellular carcinoma following palliative liver resection. CJTCMP,
2010, 25 (12): 1988–1990.
30 The Experimental research on the in vitro
inhibitory effects of medicated serum with Chinese herbal compound Songyou
Yinon human hepatocellular carcinoma MHCC97H cells with high metastatic
potential. Chinese Archives of Traditional Chinese Medicine, 2010, 28 (11):
2396–2398.
31 Effects of MIM-B gene on invasive and
metastatic potentials of human hepatoceHuar carcinoma MHCC97Hcells. Chin J
Hepatol, 2010, 18 (12): 914–918.
Corresponding
Author
1 Preliminary Research on Formula
Optimization of Chinese Herbal Compound Songyou Yin. Chinese Archives of
Traditional Chinese Medicine, 2015, 33 (11): 2613–2616
2 Evaluation of a new mark-pen in
preoperative application for patients with varicose vein of lower extremity.
Hebei Medical Journal, 2013, 35 (19): 2885–2887.
3 Risk factors for psychiatric symptoms
after liver transplantation. Chin J Misdiagn, 2011, 11 (19): 4537–4538.
4 Identification and treatment for patients
with psychonosema following liver transplantation. Chin J Transplant
(Electronic Edition), 2010, 4 (3): 229–231.
5 Research advance on anti-tumor effects
and mechanisms of Traditional Chinese Medicine. Medical Recapitulate, 2010, 16
(3): 386–389.
6 A case of spontaneous subdural hematoma
falx. Chin J Misdiagn, 2010, 10 (4): 993.